MIM Software receives FDA clearance to market products running on tablets through thin client technology

Michael Walter | | Health Imaging | Medical Imaging

MIM Software announced this week it has received 510(k) clearance from the FDA. The company can now market its full product line running on tablets through thin client technology.

Jerimy Brockway, MIM vice president of engineering, said in a prepared statement that this makes using the company’s products much more convenient.

“Receiving 510(k) clearance gives MIM users the ability to access all of the technology and power of our leading products on a mobile device,” Jerimy Brockway, MIM vice president of engineering, said in a prepared statement. “This allows physicians to work on a patient case on the same software after they leave the office.”

MIM also announced that it will be demonstrating its product line from booth # 931 at the Society of Nuclear Medicine and Molecular Imaging 2016 Annual Meeting in San Diego, Calif., June 11-15. 

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

FDA says CT scans sometimes damage implantable cardiac electronic devices
Bilingual people have more efficient brains, imaging study shows
Use of AI opportunistic screening in CT for cardiovascular disease
ChatGPT is overly worried about ED patients
Low doses of radiation still increase risk of leukemia, lymphoma and myeloma
ACR offers resources to achieve radiology AI best practices

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.